Trial data on the recent injectable obesity compounds has documented meaningful lean-mass loss alongside fat loss, and nearly all of them require injection. Bioglutide, developed under the code NA-931, is interesting because its trial readouts push against both traits. It is an oral, once-daily small molecule, and the data presented so far centers on weight loss reported without muscle loss.
The mechanism is unusual. Where retatrutide is a triple agonist and tirzepatide a dual, bioglutide is described as a quadruple agonist — informally tagged "GLP-4" in research circles for its four targets: IGF-1, GLP-1, GIP, and glucagon. The IGF-1 arm is the piece that separates it from the injectable incretin field, and it is what the trial data links to the muscle-preservation signal.
Everything below is trial-reported and, for now, largely conference-reported rather than peer-reviewed. Here is what the Phase 1 and Phase 2 data has actually documented, benefit by benefit.
Research-context information only. Bioglutide (NA-931) is an investigational drug not approved by the FDA. Protocols, doses, and reactions reported below come from published clinical trials and self-reported community sources. This article reports what has been documented, not what should be done. Possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. Consult a licensed physician for personal medical decisions.
The Weight Loss the Phase 2 Trial Reported
The lead benefit is body weight reduction. In the Phase 2 study (NCT06564753), presented at the American Diabetes Association's 2025 Scientific Sessions as late-breaking abstract 2189-LB in Diabetes, trial subjects on the 150mg/day oral dose averaged 13.8% mean body weight loss over the study period. After placebo adjustment, the abstract reported a 12.4% placebo-adjusted difference.
The responder data is what stands out. The abstract reported that 72% of subjects on 150mg/day reached at least 12% weight loss, versus 2% on placebo. That is a wide separation between arms for an oral agent, and it is the figure the readout has leaned on.
An earlier Phase 1 readout, published in Endocrine Practice, reported roughly 10-13% weight loss at 12 weeks. Read together, the two readouts describe a dose- and time-dependent effect that the Phase 2 data extended. All of these are trial-reported averages across a study population — not outcomes attributable to any individual, and not comparable head-to-head with the longer Phase 3 injectable trials that have run 72 weeks.
Reported Muscle Preservation via the IGF-1 Arm
The second reported benefit — and the one that most differentiates bioglutide from the injectable field — is body composition. A separate ADA 2025 presentation, abstract 143-OR in Diabetes, was framed explicitly around reducing body weight without muscle loss.
This is attributed to the IGF-1 receptor component of bioglutide's reported quadruple-agonist design. The standard critique of high-efficacy incretin weight loss is that a meaningful share of the lost mass is lean tissue; the stated rationale for adding an IGF-1 arm is to bias the loss toward fat while sparing muscle. In the trial framing, that is the mechanism behind the "without muscle loss" claim.
This benefit carries the heaviest caveat of any in this article. It is conference-reported, drawn from an abstract title and the trial's mechanistic explanation, not from an independently peer-reviewed body-composition dataset with DEXA endpoints published in full. The direction of the signal is what the trial reported; the durability and magnitude are what independent Phase 3 data would have to confirm.
Affiliate disclosure: The Peptide Catalog earns a commission on purchases made through the vendor links below.
Where to compare pricing. Bioglutide isn't in our vetted vendor lineup yet. Retatrutide covers three of bioglutide's four incretin targets but not the IGF-1 arm credited with the muscle-sparing signal, so it is a mechanism-class reference rather than an equivalent. Readers tracking this class can see current retatrutide vendor pricing and COA-verified options, or browse all coupon codes for up to 50% off.
